Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bruker Daltonics

This article was originally published in The Gray Sheet

Executive Summary

Firm goes public Aug. 4 via initial offering of 8 mil. shares at $13 each under the Nasdaq symbol "BDAL." The Billerica, Massachusetts maker of mass spectrometry life science tools plans to use gross proceeds of $104 mil. for the expansion of sales and marketing capabilities, R&D, debt repayment, working capital, potential acquisitions and other general corporate purposes. UBS Warburg LLC is the lead manager for the offering, with CIBC World Markets and Thomas Weisel Partners LLC co-managing. The underwriters hold an over-allotment option of 1.2 mil. additional shares



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts